Skip to content
HowShorted

PTC Therapeutics, Inc. short interest in 2019

In 2019, PTC Therapeutics, Inc.'s disclosed short interest ran from 8.82% of shares outstanding on 15 Jan 2019 to 5.66% on 31 Dec 2019, a change of -3.16 percentage points. The year's high was 11.36% on 28 Feb 2019 and its low 5.15% on 13 Dec 2019, averaging 7.99% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.62 days on 30 Aug 2019. Full history: PTC Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for PTC Therapeutics, Inc. in 2019

2019 in figures

Start of year
8.82% (15 Jan 2019)
End of year
5.66% (31 Dec 2019)
Change
-3.16 pp
High
11.36% (28 Feb 2019)
Low
5.15% (13 Dec 2019)
Average
7.99%
Highest days to cover
15.62 (30 Aug 2019)
SEC filings marked
9

Every report in 2019

PTC Therapeutics, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 20198.82%5.63results (8-K)
31 Jan 201910.53%4.02
15 Feb 201910.58%7.83
28 Feb 201911.36%5.58results (8-K)
15 Mar 20199.23%5.8410-K filed
29 Mar 20199.65%8.38
15 Apr 20199.00%8.60
30 Apr 20197.78%7.23
15 May 20198.27%3.8210-Q filed, results (8-K)
31 May 20198.47%5.92
14 Jun 20198.56%6.70
28 Jun 20197.27%5.00
15 Jul 20196.86%9.63
31 Jul 20196.48%9.02
15 Aug 20196.62%8.3110-Q filed, results (8-K)
30 Aug 20196.64%15.62
13 Sep 20196.85%10.67
30 Sep 20198.50%3.63
15 Oct 20198.91%7.14
31 Oct 20199.03%7.7710-Q filed, results (8-K)
15 Nov 20196.12%5.56
29 Nov 20195.36%3.88
13 Dec 20195.15%4.22
31 Dec 20195.66%7.39

See also: PTC Therapeutics, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.